NASD · Healthcare · Biotechnology · USA
Alnylam Pharmaceuticals Inc is a large cap company (market value between $10 billion and $200 billion) in the Biotechnology industry.
Alnylam Pharmaceuticals is a biopharmaceutical company developing medicines based on RNA interference technology that silences disease-causing genes. The company has six approved RNAi therapeutics marketed for rare diseases including hereditary amyloidosis, acute hepatic porphyria, primary hyperoxaluria, and hemophilia, with additional products commercialized through collaborators. The company operates clinical programs targeting genetic diseases and prevalent conditions across multiple tissue types.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Alnylam Pharmaceuticals Inc stock.
Overvalued: intrinsic value $174.98 per share, market price $233.29, margin of safety -33.3% (as of 2026-10-19).
Discounting its cash flows at 7.8% (average of 3 methods) values the shares at $174.98; the price of $233.29 is 33% above that value, and 82% of that value comes from beyond year five.
Leak Score: 65/100 on 11 of 12 signals (Faint Leak).
17 more funds hold it; the full list is part of the paid plan.
44 more in this industry show a wider margin of safety.
ALNY is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 7.8% (average of 3 methods) values the shares at $174.98; the price of $233.29 is 33% above that value, and 82% of that value comes from beyond year five.
$174.98 per share (as of the 2026-10-19 close), against a market price of $233.29. That is a margin of safety of -33.3%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
65 out of 100, which we rate "Faint Leak", on 11 of 12 value investing signals.